Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2018		$ 2,558	$ 9,727,124	$ (4,952,443)	$ 4,777,239
Balance, shares at Dec. 31, 2018		2,558,419
Stock-based compensation - stock options			54,382		54,382
Stock-based compensation - restricted stock units			22,500		22,500
Net loss				(1,528,056)	(1,528,056)
Balance at Mar. 31, 2019		$ 2,558	9,804,006	(6,480,499)	3,326,065
Balance, shares at Mar. 31, 2019		2,558,419
Stock-based compensation - stock options			79,962		79,962
Stock-based compensation - restricted stock units			22,500		22,500
Net loss				(1,428,675)	(1,428,675)
Balance at Jun. 30, 2019		$ 2,558	9,906,468	(7,909,174)	1,999,852
Balance, shares at Jun. 30, 2019		2,558,419
Issuance of common stock in September capital raise		$ 70	499,929		499,999
Issuance of common stock in September capital raise, shares		69,114
Stock-based compensation - stock options			116,640		116,640
Stock-based compensation - restricted stock units			22,500		22,500
Net loss				(2,354,083)	(2,354,083)
Balance at Sep. 30, 2019		$ 2,628	10,545,537	(10,263,257)	284,908
Balance, shares at Sep. 30, 2019		2,627,533
Balance at Dec. 31, 2019		$ 2,628	10,651,073	(12,781,660)	(2,127,959)
Balance, shares at Dec. 31, 2019		2,627,533
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs	$ 4		25,318,702		25,318,706
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs, shares	3,879
Issuance of Common Stock in public offering, net of offering costs		$ 285	1,867,295		1,867,580
Issuance of Common Stock in public offering, net of offering costs, shares		284,875
Issuance of Common Stock in Proteon Private Placement, net of offering costs		$ 1,897	12,411,440		12,413,337
Issuance of Common Stock in Proteon Private Placement, net of offering costs, shares		1,896,888
Reverse business combination		$ 1,033	34,531,594		34,532,627
Reverse business combination, shares		1,033,907
Stock-based compensation - stock options			368,135		368,135
Stock-based compensation - restricted stock units			2,429,672		2,429,672
Net loss				(10,060,257)	(10,060,257)
Balance at Mar. 31, 2020	$ 4	$ 5,843	87,577,911	(22,841,917)	64,741,841
Balance, shares at Mar. 31, 2020	3,879	5,843,203
Balance at Dec. 31, 2019		$ 2,628	10,651,073	(12,781,660)	(2,127,959)
Balance, shares at Dec. 31, 2019		2,627,533
Balance at Sep. 30, 2020	$ 8	$ 10,522	232,567,265	(37,952,032)	194,625,763
Balance, shares at Sep. 30, 2020	8,027	10,521,840
Balance at Mar. 31, 2020	$ 4	$ 5,843	87,577,911	(22,841,917)	64,741,841
Balance, shares at Mar. 31, 2020	3,879	5,843,203
Stock-based compensation - stock options			514,054		514,054
Stock-based compensation - restricted stock units			1,314,668		1,314,668
Net loss				(7,140,030)	(7,140,030)
Balance at Jun. 30, 2020	$ 4	$ 5,843	89,406,633	(29,981,947)	59,430,533
Balance, shares at Jun. 30, 2020	3,879	5,843,203
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs	$ 4		66,283,548		66,283,552
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs, shares	4,148
Settlement of RSUs		$ 21	(21)
Settlement of RSUs, shares		20,870
Exercise of stock options		$ 58	530,243		530,301
Exercise of stock options, shares		57,767
Issuance of Common Stock in public offering, net of offering costs		$ 4,600	73,566,060		73,570,660
Issuance of Common Stock in public offering, net of offering costs, shares		4,600,000
Stock-based compensation - stock options			1,473,629		1,473,629
Stock-based compensation - restricted stock units			1,307,173		1,307,173
Net loss				(7,970,085)	(7,970,085)
Balance at Sep. 30, 2020	$ 8	$ 10,522	$ 232,567,265	$ (37,952,032)	$ 194,625,763
Balance, shares at Sep. 30, 2020	8,027	10,521,840